In clinical trials (mainly in IBD and CKD patients with IDA), ferric maltol significantly raised Hb; mean Hb increases were on the order of ≥2 g/dL by 12–16 weeks of therapy. The gene discussed is GSTM1; the disease is chronic kidney disease.